Pulmonary Arterial Hypertension (PAH) Market

Pulmonary Arterial Hypertension (PAH) Market Size Survey Report – In a Glance

As per the survey report on global Pulmonary arterial hypertension (PAH) market, the market is projected to foresee a CAGR of CAGR value 5.7% between 2024-2033, and further generate a market size of USD 13.3 billion revenue by the end of 2033. In the year 2024, the market size was valued at USD 8.1 billion revenue.

• The global pulmonary arterial hypertension (PAH) market is projected to grow on account of the surging cases of heart diseases and high blood pressure.
• In Japan, the pulmonary arterial hypertension (PAH) market growth can be attributed to the growing preference for westernized eating habits and lifestyle choices.
• KDMI analyst’s growth analysis foresees financial burden of PAH treatment to challenge the market growth.
• North America, having the highest market share in the pulmonary arterial hypertension (PAH) market, is projected to dominate the global market.

Pulmonary Arterial Hypertension (PAH) Market Analysis

Pulmonary arterial hypertension (PAH) is a long-standing chronic medical condition marked by excessive pressure in the pulmonary arteries straining the heart to work harder to pump blood into the lungs. It is caused by arterial narrowing or stiffness. Besides, if its symptoms like shortness of breath, chest pain or fatigue are ignored or left untreated, it may progress to severe heart dysfunction including heart failure. Nowadays, the mounting stress in day-to-day life has led to a surge in cardiac diseases and various heart-related conditions. A report from the World Heart Federation (WHF) revealed that there were near about 20.5 million deaths from cardiovascular diseases in 2021. This upward trend in cardiac illnesses and hypertension accelerates the PAH market growth because of the rising demand for PAH drugs and treatments. Bayer, Gilead Sciences, Inc., Johnson & Johnson, are some of the significant parties in the global market for pulmonary arterial hypertension (PAH).

Analyst’s Observation on Japan Pulmonary Arterial Hypertension (PAH) Market Survey

Japanese view food as more than a mere meal and consider it as a way to maintain good health. Their traditional diet usually consists of unprocessed, low-fat, low-sugar, and farm-fresh ingredients. However, the market growth for pulmonary arterial hypertension (PAH) in the country is mainly due to the growing preference for westernized eating habits and lifestyle choices in the current era. High blood pressure ranks among the top factors of fatalities in Japan after smoking and near about 43 million people are hypertensive. Therefore, the growing trend of western style eating and unhealthy lifestyles is giving birth to multiple fatal diseases. This, in turn, is raising awareness and demand for PAH treatments which is eventually driving the PAH market in the region. Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd., are some of the significant parties in the market for pulmonary arterial hypertension (PAH) in Japan.

Pulmonary Arterial Hypertension (PAH) Market Growth Drivers and Challenges

Growth Drivers

Greater public awareness of PAH:

Pulmonary arterial hypertension (PAH) is a rare yet serious health condition where heightened pressure in the lung’s arteries forces the heart to exert extra effort, possibly leading to cardiac failure. Near about 56.5 million cases of heart failure (HF) were recorded across the globe in 2021 out of which 27.3 million were women and 29.2 million were men. Over recent years, the occurrence of PAH has been on the rise. Moreover, growing knowledge among the population is driving the demand for advanced treatment methods. Additionally, awareness campaigns are also promoting related medical tests, leading to better detection rates. Therefore, the heightened awareness and enhanced knowledge of PAH are driving the industry growth by encouraging early detection and adoption of treatments.

Market approval of new PAH medicines:

Innovative medications can protect lives and enrich the health of millions of people. The cutting edge innovations including vaccines, cell therapies, over-the-counter drugs, medical devices, and surgical or other treatment procedures can curb the progression of diseases. However, the increasing research activities in drug discovery and development across the globe are fueling the pulmonary arterial hypertension (PAH) market. Advanced drugs or therapies offer greater efficiency, reduced side effects, and better disease control. According to the World Health Organization, almost one-quarter of the world has no access to essential medicines which is equivalent to 2 billion people approximately. Moreover, the newly-sanctioned drugs enhance accessibility, increasing adoption rates among medical professionals and patients. Therefore, as scientific discoveries advance, the PAH market continues to expand, driven by modern medical solutions.

Restraints

Financial burden of PAH treatment:

Expensive PAH treatments curb market growth by limiting access for patients. Costly medications and long-term treatment pose financial barriers reducing patient compliance and slower treatment adoption. Additionally, lengthy drug approval processes further incur huge costs. Overall, these lead to delayed diagnoses and treatment, impeding the market progress and patient outcomes.

Potential risks of PAH medicines:

Adverse reactions such as nausea, fatigue, or headaches may prompt patients to stop their treatment or choose alternate medications leading to ineffective disease management and poorer patient outcomes which ultimately decelerates the market progression. Hence, PAH medication side effects can restrict market growth by lowering patient adherence and treatment acceptance.

Pulmonary Arterial Hypertension (PAH) Market Segmentation

Our experts at KD Market Insights have segmented the global pulmonary arterial hypertension (PAH) market research report as:

Pulmonary Arterial Hypertension (PAH) Market Regional Synopsis

North America is at the forefront of the pulmonary arterial hypertension (PAH) market and is majorly driven by its strengthening tactical partnerships and collaborations among key stakeholders. Besides that, the progressive healthcare systems, increased awareness among the public and favorable government initiatives in Canada and the United States further fuels the market within the region. The United States holds the largest share of the regional PAH market within the given period because of the presence of highly qualified physicians, increased hospital visits along with promising drug development pipeline in the country. According to statistical findings, the share of healthcare in the US economy will be 20% by 2024. In addition to that, healthcare spending is anticipated to account for 9.6% of the GDP in the United States by 2024 in comparison with the 17.4% share of the GDP in 2013.

Asia-Pacific (APAC) is encountering the quickest market surge during the forecasted period. The region functions as a central point for pharmaceutical businesses. This is mainly due to expansive distribution channels and trade connections. Furthermore, the market is also steered by the increasing use of generic drugs, consumer demands, economic expansion and progressing healthcare infrastructure. India is also upgrading the PAH market due to its massive population, fast economic progression, and strengthened healthcare systems. In addition to that, Japan’s economic progress is likely to expand at a rate beyond its expected growth capacity. China is also contributing a significant part to the regional market. It has implemented the world’s largest planned urban transformation program, thereby, promoting healthcare development. Also, numerous policies have supported its overall healthcare framework and economic growth goals.

In Europe, the existence of government organizations such as the European Medicines Agency (EMA) and the European Society of Cardiology supporting early detection and preventive screening of PAH are mainly expected to drive PAH market expansion in the coming future. Moreover, the UK is at the forefront of the development of the market in the region due to its increasing elderly demographic. Several factors are responsible for the market evolution in the area such as the rising occurrence of chronic diseases, growing PAH awareness, and expanding availability of medical solutions.

As per our analysts at KD Market Insights, the following five players lead the North America Pulmonary arterial hypertension (PAH) market growth:

• Pfizer Inc.
• Merck & Co. Inc.
• Keros therapeutics
• Liquidia Corporation
• Bristol-Myers Squibb Company

Pulmonary Arterial Hypertension (PAH) Market Competitive Landscape

Some of the key players who top the global pulmonary arterial hypertension (PAH) market share:

• United Therapeutics Corporation
• Bayer
• Gilead Sciences, Inc.
• Johnson & Johnson
• Viatris Inc.
• GlaxoSmithKline
• Sandoz Inc.
• Lupin Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries, Inc.
• Teva Pharmaceutical Industries Ltd.

1. Executive Summary
   1. Market Overview
   2. Key Findings
   3. Market Trends
   4. Market Outlook
2. Introduction
   1. Scope of the Report
   2. Research Methodology
   3. Definitions and Assumptions
   4. Acronyms and Abbreviations
3. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
   4. Challenges
4. Global Pulmonary Arterial Hypertension (PAH) Market
   1. Market Overview
   2. Market Size and Forecast
   3. Market Segmentation
      1. By Drug class
      2. By Route of administration
      3. By Type
      4. By Distribution channel
      5. By Region
5. Market Segmentation by Drug class
   1. 1. Endothelin Receptor Antagonists
      2. SGC Stimulators
      3. PDE-5 Inhibitors
      4. Prostacyclin & Prostacyclin Analogs
      5. Others
6.  Market Segmentation by Route of administration
   1. 1. Oral
      2. Intravenous/ Subcutaneous
      3. Others
7.  Market Segmentation by Type
   1. 1. Innovative
      2. Generics
8.  Market Segmentation by Distribution channel
   1. 1. Hospitals
      2. Retail Pharmacies
      3. Online Pharmacies
9. Regional Analysis
   1. North America
      1. United States
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      2. Canada
         1. Market Size and Forecast
         2. Key Trends and Developments
      3. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      4. Mexico
         1. Market Size and Forecast
         2. Key Trends and Developments
   2. Market Analysis by Drug class, Route of administration, Type and Distribution channel
   3. Europe
      1. United Kingdom
         1. Market Size and Forecast
         2. Key Trends and Developments
      2. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      3. Germany
         1. Market Size and Forecast
         2. Key Trends and Developments
      4. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      5. France
         1. Market Size and Forecast
         2. Key Trends and Developments
      6. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      7. Italy
         1. Market Size and Forecast
         2. Key Trends and Developments
      8. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      9. Spain
         1. Market Size and Forecast
         2. Key Trends and Developments
      10. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      11. Rest of Europe
          1. Market Size and Forecast
          2. Key Trends and Developments
   4. Market Analysis by Drug class, Route of administration, Type and Distribution channel
   5. Asia Pacific
      1. China
         1. Market Size and Forecast
         2. Key Trends and Developments
      2. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      3. Japan
         1. Market Size and Forecast
         2. Key Trends and Developments
      4. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      5. India
         1. Market Size and Forecast
         2. Key Trends and Developments
      6. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      7. Australia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Drug class, Route of administration, Type and Distribution channel
         4. South Korea
         5. Market Size and Forecast
         6. Key Trends and Developments
      8. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      9. Rest of Asia Pacific
         1. Market Size and Forecast
         2. Key Trends and Developments
   6. Market Analysis by Drug class, Route of administration, Type and Distribution channel
   7. Latin America
      1. Brazil
         1. Market Size and Forecast
         2. Key Trends and Developments
      2. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      3. Argentina
         1. Market Size and Forecast
         2. Key Trends and Developments
      4. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      5. Colombia
         1. Market Size and Forecast
         2. Key Trends and Developments
      6. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      7. Rest of Latin America
         1. Market Size and Forecast
         2. Key Trends and Developments
   8. Market Analysis by Drug class, Route of administration, Type and Distribution channel
   9. Middle East & Africa
      1. South Africa
         1. Market Size and Forecast
         2. Key Trends and Developments
      2. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      3. Saudi Arabia
         1. Market Size and Forecast
         2. Key Trends and Developments
      4. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      5. UAE
         1. Market Size and Forecast
         2. Key Trends and Developments
      6. Market Analysis by Drug class, Route of administration, Type and Distribution channel
      7. Rest of Middle East & Africa
         1. Market Size and Forecast
         2. Key Trends and Developments
10. Market Analysis by Drug class, Route of administration, Type and Distribution channel
11. Competitive Landscape
    1. Market Share Analysis
    2. Company Profiles
    3. United Therapeutics Corporation
    4. Bayer
    5. Gilead Sciences, Inc.
    6. Johnson & Johnson
    7. Viatris Inc.
    8. GlaxoSmithKline
    9. Sandoz Inc.
    10. Lupin Pharmaceuticals, Inc.
    11. Sun Pharmaceutical Industries, Inc.
    12. Teva Pharmaceutical Industries Ltd.
12. Strategic Recommendations
13. Appendix
    1. List of Tables
    2. List of Figures
14. References